Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of FTP-198 in Healthy Volunteers
NCT04526496Phase 1Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FTP-198 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2020; status: completed.
02
Drugs
FTP-198
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04526496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526496.